Bio­gen spells out re­mark­able ef­fi­ca­cy da­ta in Alzheimer's for ad­u­canum­ab, but safe­ty threat per­sists

Saman­tha Budd Hae­ber­lein, Bio­gen

Shares of Bio­gen jumped Thurs­day af­ter­noon af­ter an up­dat­ed as­sess­ment of the re­mark­ably pos­i­tive da­ta they’ve been col­lect­ing from the PRIME study of their Alzheimer’s drug hope­ful ad­u­canum­ab was leaked among in­vestors and then quick­ly spread on­line.

Aside from the ker­fuf­fle over how the da­ta first be­gan to sur­face, a close look at the full set of re­sults re­vealed a sur­pris­ing­ly pos­i­tive read­out that will help ig­nite re­newed en­thu­si­asm for Bio­gen’s prospects in what is per­haps the tough­est field in R&D — though a big safe­ty is­sue re­mains a key con­cern.

Look­ing over the da­ta from 196 pa­tients, in­ves­ti­ga­tors re­port­ed that they tracked sig­nif­i­cant de­creas­es in amy­loid plaque bur­den in the brains of pa­tients tak­ing a titrat­ed 10 mg dose of the drug “dur­ing 12 months of treat­ment in ApoE ε4-pos­i­tive pa­tients with pro­dro­mal or mild AD com­pared with place­bo.” And they linked that to a clear and sig­nif­i­cant slow­ing of the dis­ease.

Bio­gen’s shares end­ed up 1.5% at the close, af­ter bounc­ing up and down as the da­ta were passed around. In pre-mar­ket trad­ing shares spiked 3.75%.

In­ves­ti­ga­tors were able to track a slow­ing in the de­cline among pa­tients tak­ing a titrat­ed dose of ad­u­canum­ab. And the most com­mon ad­verse ef­fect, ARIA, “ap­peared” to be re­duced among the titrat­ed drug arm com­pared to the high­er fixed dose among pa­tients with the ApoE4 gene, which may pre­dis­pose them to the dis­ease.

The slow­ing in the Clin­i­cal De­men­tia Rat­ing-Sum of Box­es (CDR-SB, which mea­sures cog­ni­tive and func­tion­al per­for­mance) scale was sta­tis­ti­cal­ly sig­nif­i­cant in the titrat­ed arm com­pared to the place­bo group. And the in­ves­ti­ga­tors say they felt the da­ta they had gath­ered sup­port­ed the de­sign of their Phase III study, which puts this drug to the piv­otal test.

There ap­peared to be a clear dose re­sponse to the drug, which is what in­ves­ti­ga­tors like to see.

In a re­lease is­sued late Thurs­day, Bio­gen spelled out the changes in both the CDR-SB and MMSE mea­sures, break­ing out the scores by dos­es com­pared to a place­bo. For the CDR-SB Group, the place­bo arm wors­ened by an av­er­age of 1.89 points at 54 points. That was close to the 1.69 point drop for the 1 mg group, but far worse than the 0.70 in the titra­tion arm. The 10 mg group had the best score of 0.63.

On the MMSE score, the place­bo arm wors­ened an av­er­age of 2.45 points, but that dropped to 0.55 in the 10 mg arm and 1.00 in the titra­tion arm.

ARIA, though, is clear­ly a per­sis­tent prob­lem. The in­ci­dence of ARIA-E in ApoE4 car­ri­ers in the fixed-dose arms was 5 per­cent in the 1 mg/kg and 3 mg/kg arms, 43 per­cent in the 6 mg/kg arm and 55 per­cent in the 10 mg/kg arm. The in­ci­dence of ARIA-E in ApoE4 car­ri­ers in the titra­tion arm was 35 per­cent.

Bri­an Sko­r­ney, Baird an­a­lyst

This is some of the most en­cour­ag­ing da­ta the Alzheimer’s field has seen in years, leav­ing ad­u­canum­ab as one of the top prospects now in late-stage de­vel­op­ment. While much more safe­ty and ef­fi­ca­cy da­ta re­main to be gath­ered in piv­otal stud­ies, its suc­cess at this stage marks a po­ten­tial turn­ing point, which could be rich­ly re­ward­ed by a mar­ket des­per­ate for an ef­fec­tive ther­a­py, es­pe­cial­ly so soon af­ter Eli Lily’s so­la flopped.

“Both ab­stracts high­light sig­nif­i­cant de­clines in plaque bur­den and as­so­ci­at­ed ben­e­fits in terms of the rate of clin­i­cal de­cline, with the titra­tion co­hort show­ing a stat sig ben­e­fit on CDR-SB com­pared to place­bo at 12 months,” not­ed Bri­an Sko­r­ney, who was en­cour­aged by the ex­ten­sion da­ta. He added:

 Of the 165/196 pa­tients in the PRIME study on a fixed dose, 91 were evalu­able out to 24 months. Pa­tients switched from place­bo to ad­u­canum­ab did show de­clines in plaque bur­den and slow­er rates of cog­ni­tive/func­tion­al de­cline. Pa­tients in the 10mg/kg and 6mg/kg dose groups re­main­ing on drug saw con­tin­ued ben­e­fit out to 24 months and an even more sig­nif­i­cant re­sponse than those who were switched on­to drug af­ter place­bo. There were no new cas­es of ARIA for those con­tin­u­ing on ad­u­canum­ab in the LTE. The one year fol­low up should be in­ter­pret­ed with cau­tion as pa­tients know they are on treat­ment and the clin­i­cal mea­sure­ments are sub­ject to high vari­abil­i­ty.

Ad­u­canum­ab is a crit­i­cal­ly im­por­tant drug for Bio­gen, which has ex­pe­ri­enced a se­ries of pipeline ups and downs as its block­buster Tec­fidera has be­gun to wane on the big mul­ti­ple scle­ro­sis mar­ket.

“The da­ta at CTAD sup­port the pos­i­tive re­sults we have seen in our Phase 1b study of ad­u­canum­ab, and they pro­vide in­sight in­to the ob­served ef­fects in pa­tients treat­ed for up to two years,” said Saman­tha Budd Hae­ber­lein, vice pres­i­dent, clin­i­cal de­vel­op­ment at Bio­gen. “We are com­mit­ted to ad­vanc­ing our glob­al Phase 3 pro­gram for ad­u­canum­ab as well as the sci­en­tif­ic un­der­stand­ing of Alzheimer’s dis­ease so we can help iden­ti­fy a treat­ment for the many peo­ple af­fect­ed by this ter­ri­ble dis­ease.”

https://twit­ter.com/Arm­strong­Drew/sta­tus/806952994855997440

Gilead CEO Dan O'­Day of­fers a de­tailed ex­pla­na­tion on remde­sivir ac­cess — re­as­sur­ing an­a­lysts that Covid-19 da­ta are com­ing fast

After coming under heavy fire from consumer groups ready to pummel them for grabbing the FDA’s orphan status for remdesivir — reserved to encourage the development of rare disease therapies — Gilead CEO Daniel O’Day had some explaining to do about the company’s approach to providing access to this drug to patients suffering from Covid-19. And he set aside time over the weekend to patiently explain how they are making their potential pandemic drug available in a new program — one he feels can better be used to address a growing pack of infected patients desperately seeking remdesivir under compassionate use provisions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Ven­ture Cap­i­tal as a Strate­gic Part­ner: Fu­el­ing In­no­va­tion be­yond Fi­nance

The average level of investment required for a biotech start-up to succeed is increasing every year, elevating the pressure even further on venture capital to make smart financial investments. Financial investment alone, however, does not always guarantee that exciting innovations can be transformed into real businesses that make a meaningful difference to patients.

Beyond just capital

At Astellas Venture Management (AVM) – a wholly-owned venture capital organization within Astellas, headquartered in the San Francisco Bay Area – capital is just one of the ingredients we offer to add value to our biotechnology investments and partnerships. We generally take a strategic investor approach for companies in our invested portfolio, providing access to expertise, technology and/or resources in addition to the injection of finance. An equity investment from AVM can include access to Astellas’ research and development (R&D) capabilities and expertise, and a global network of partner academic institutions and biotechnology companies, to help advance and accelerate the start-up’s innovation.

Covid-19 roundup: In­ter­cept, blue­bird and a grow­ing list of biotechs feel the pain as pan­dem­ic man­gles FDA, R&D sched­ules

Around 100 staffers at Boston area hospitals have now tested positive for Covid-19, spotlighting the growing risk that the pandemic will sideline many of the most essential workers in healthcare as caseloads peak in the US and around the globe. With more than 3,400 deaths, Spain has become the latest country to surpass the official death count attributed to the new coronavirus in China, where the outbreak originated. As of Thursday morning, confirmed global cases had crossed 470,000 and the death count eclipsed 21,000.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

Two days after Gilead won orphan drug status for remdesivir as a potential treatment for Covid-19, they’re handing it back.

The company was slammed from several sides after Gilead reported that the FDA had come through with the special status, which comes with 7 years of market exclusivity, the waiver of FDA fees and some tax credits as well. Typically, everyone who can get orphan status lands it without much of a fuss, but Democratic presidential candidate Bernie Sanders, Public Citizen and other consumer groups were outraged.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Mod­er­na CEO Stéphane Ban­cel out­lines a short path for emer­gency use of a coro­n­avirus vac­cine

NIAID director Anthony Fauci has left no doubts that it takes 12 to 18 months to get a new vaccine tested and in commercial use, in the best of circumstances. But in times of a global emergency — like these — maybe there’s another, faster route to follow.

In an SEC filing on Tuesday, Moderna $MRNA staked out a record-setting pathway to getting their mRNA vaccine into the frontline of the healthcare response as early as this fall. The SEC filing notes that CEO Stéphane Bancel told Goldman Sachs that an emergency use approval could allow the vaccine to go to healthcare workers and certain individuals in a matter of months — presumably provided the NIH sees the safety and efficacy data they would need from the Phase I.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Caught in a Covid-19 mael­strom, Eli Lil­ly locks down clin­i­cal tri­als as multi­bil­lion-dol­lar R&D ops de­rail

The Covid-19 pandemic has derailed Eli Lilly’s $6 billion R&D operations.

The pharma giant reported Monday morning that it has decided to hit the brakes on most new study starts and pause enrollment for most ongoing studies. Lilly adds that it is continuing dosing for ongoing studies, “but with study-by-study consideration.”

The pandemic has severely disrupted healthcare systems around the globe, says Lilly, making it difficult or impossible to conduct studies at many research sites. And there’s no timeline for when it expects to get back on track.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

You can add Pfizer, Merck and — as we found out Friday morning — Vertex to the growing list of pharma giants hitting the pause button on a range of clinical trials. But not everyone in R&D is getting a red light.

Vertex says that it’s doing its best to keep working its pipeline strategy, coming up with a plan “to enable virtual clinic visits and home delivery of study drug to ensure study continuity and medical monitoring, and to facilitate study procedures.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Bris­tol My­ers sus­pends clin­i­cal tri­als, grounds field team; Vir ush­ers an­ti­body can­di­dates to hu­man test­ing

The global nature of the Covid-19 pandemic is manifesting more profoundly every day. With Spain’s death toll now surpassing China’s and India on full lockdown, the number of confirmed cases around the world has exceeded 436,000 while recoveries edged close to 112,000.

While the outbreak derails R&D at another pharma giant, several drugmakers have some encouraging updates on both experimental and repurposed molecules. Philanthropic campaigns in anticipation of the economic fallout continue. An Australian biotech is taking extreme measures to hunker down. There’s also an alternative epidemiology model emerging out of the UK, stirring up more discussion regarding the true extent of the infections in the country.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.

As share buy­backs come un­der scruti­ny, what's in store for the bio­phar­ma in­dus­try?

Stock buybacks are not to be permitted for companies that will be bailed out in the coronavirus stimulus package, Congressional leaders have signaled. To what degree the biopharma industry has relied on buybacks for earnings growth in recent years, and if the trend continues, are the big questions as scrutiny into the practice heightens and balance sheets weaken with the coronavirus pandemic wreaking havoc on global economies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 76,900+ biopharma pros reading Endpoints daily — and it's free.